The international firm is one of several pharmaceutical companies emphasizing new single-cell technologies to improve existing drugs and find new ones.
The deals cover Native Antigen's native and recombinant viral and bacterial antigens, antibodies, and immunoassays in certain European and Asian markets.
The partnership follows a strategic collaboration between Twist and LakePharma, announced last week, that involves the same technology.
The firms will use AbCellera's antibody discovery platform, which combines a variety of technologies including next-generation sequencing and bioinformatics.
As part of the Human Vaccines Project, researchers sequenced samples from three adults and three infants to identify sets of shared and unique circulating B cell receptors.
The companies will use Berkeley Lights' technology to improve Pfizer's monoclonal antibody discovery and gene editing workflows.
The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.
The custom-made software will also allow Twist's biopharmaceutical customers to access a proprietary G-protein coupled receptor target library.
Researchers discuss the need for antibody standards at a meeting, NPR reports.
The group this week published a set of initial guidelines for antibody validation meant as recommendations in advance of a larger meeting later this month.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.